2 recruiting, 1 active not recruiting. 3 Phase 1, 3 Phase 2.
By phase and status
Follow A2 Biotherapeutics Inc.: new trials by email
Trials (filtered) newest first · largest first
All 3 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
A2B395, xT CDx with HLA-LOH assay - Solid Tumor, Adult, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | A2 Biotherapeutics Inc. | 240 | 2025-05-22 | 2025-09-09 |
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
A2B694, A2B543, xT CDx with HLA-LOH Assay - Solid Tumor, Adult, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | A2 Biotherapeutics Inc. | 474 | 2024-04-03 | 2026-06-12 |
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
A2B530, xT-Onco with HLA-LOH Assay - Solid Tumor, Adult, Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | A2 Biotherapeutics Inc. | 160 | 2023-04-28 | 2025-04-25 |
Conditions studied
Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (3) · Neoplasms (3) · Colonic Neoplasms (2) · Lung Neoplasms (2) · Pancreatic Neoplasms (2) · Rectal Neoplasms (2) · Recurrence (2) · Carcinoma, Renal Cell (1) · Kidney Neoplasms (1) · Mesothelioma (1) · Mesothelioma, Malignant (1) · Ovarian Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
Countries
United States (3)
Top investigators
John Welch, MD, PhD (2) · Eric Ng, MD (1)